Drug-induced vascular injury (DIVI) in preclinical studies can delay, if not terminate, a drug development program. Clinical detection of DIVI can be very difficult as there are no definitive biomarkers known to reliably detect this disorder in all instances. The preclinical identification of DIVI requires detailed microscopic examination of a wide range of tissues although one of the most commonly affected areas in rats is the mesenteric vasculature. The reason for this predisposition of mesenteric arteries in rats as well as the exact mechanism and cell types involved in the initial development of these lesions have not been fully elucidated. We hypothesized that by using a mixed culture of cells from rat mesenteric tissue, we would be able to identify an RNA expression signature that could predict the in vivo development of DIVI. Five compounds designed to inhibit Phosphodiesterase 4 activity (PDE4i) were chosen as positive controls. PDE4i's are well known to induce DIVI in the mesenteric vasculature of rats and there is microscopic evidence that this is associated, at least in part, with a proinflammatory mechanism. We surveyed, by qRT-PCR, the expression of 96 genes known to be involved in inflammation and using a Random-Forest model, identified 12 genes predictive of in vivo DIVI outcomes in rats. Using these genes, we were able to cross-validate the ability of the Random-Forest modeling to predict the concentration at which PDE4i caused DIVI in vivo.
The occurrence of drug-induced vascular injury (DIVI) in preclinical studies can have significant consequences on a drug development program, including the termination of otherwise promising therapeutics. Of particular concern is that these lesions can occur within hours of drug treatment and affected animals typically exhibit no associated clinical effects and often have no correlating abnormalities in routine clinical pathology measures (Kerns et al., 2005; Mikaelian et al., 2014) .
In some instances, investigators have been able to use heart rate and/or systemic hemodynamic alterations as surrogate biomarkers to indicate the presence of vascular injury; however, this option isn't always useful as there are a number of newer drugs that have been shown to induce DIVI in preclinical studies without any correlating systemic hemodynamic effects. Other workers have reported that miRNAs in serum might have utility as peripheral biomarkers (Thomas et al., 2012) . Amongst the class of drugs not exhibiting systemic hemodynamic effects are PDE4 inhibitors (PDE4i). One common hypothesis for the mechanism underlying PDE4i-mediated DIVI is that localized changes in blood flow induce changes in hemodynamic shear stress leading to localized inflammation and ultimately vascular injury (Korkmaz et al., 2009; Swanson et al., 2014) . Oftentimes these localized effects occur in the absence of systemically detectable hemodynamic effects. It was recently shown that it is possible to observe some of these localized changes in blood flow using ultrasound imaging (Swanson et al., 2014) . In addition, selective inhibition of PDE4 in vivo with CI-1044 can induce an inflammatory expression pattern in rats (Dagues et al., 2007) . Unfortunately, neither of these approaches is practical for routine clinical monitoring in general toxicology studies in animals which is currently the gold standard for risk assessment and selecting low-risk DIVI compounds for development.
In drug development programs where DIVI has been observed with more than 1 compound, the project team chemists will often ask for an early screen for DIVI prior to safety evaluation in vivo. For projects very early in the drug development phase, when amounts of compound are quite small, this often limits screening options to in vitro assays. Regarding PDE4i-mediated DIVI in particular, we focused on the inflammatory aspect of the lesion, and postulated that the initial proinflammatory signal was derived from the mesentery itself, and not necessarily related to a direct effect instigated by primary activation of the immune system. Of interest, Dalmas et al. (2011) reported that when isolated mesenteric endothelial and vascular smooth muscle cells from rats were treated with different DIVI compounds, they saw few genes changes related to inflammation. However, several groups have suggested that a number of the inflammatory biomarkers in vascular injury and tone may arise from the perivascular tissues (Gollasch, 2012; Thomas et al., 2012; Weaver et al., 2010) . We also had previously shown that in cases of drug-induced epididymal inflammation, we were able to develop an ex vivo screen using mixed cell populations from rat epididymides and could measure the induction of pro-inflammatory genes (Chapin et al., 2014) . We attempted a similar approach here, asking whether a mixture of cell types from rat mesentery would develop a proinflammatory gene signature that could predict which compounds would pose a risk of producing DIVI in later in vivo studies. Here, we report the successful generation of an in vitro model that can predict DIVIpositive compounds, and the likely concentration at which the effect would be seen in vivo. This model is quite successful for compounds inhibiting PDE4, and much less so for compounds with other pharmacological mechanisms.
MATERIALS AND METHODS
Animals and housing. All activities involving animals were carried out in strict accordance with federal, state, local, and institutional guidelines governing the use of laboratory animals in research and were reviewed and approved by the Pfizer Institutional Animal Care and Use Committee. For these studies, adult male Sprague Dawley rats (200-500 g) were used.
Chemicals and supplies. Mesentery digestion solution was prepared as follows: Hank's Balanced Salt Solution (HBSS) without calcium chloride, magnesium chloride, and magnesium sulfate (Gibco-Life Technologies Inc. Grand Island, New York, Cat. No. 14177-095) was used as the base medium. Type II Collagenase (Gibco-Life Technologies Inc., Grand Island, New York, Cat. No. 17101-015) was added to a final concentration of 1 mg/ml. Bovine serum albumin (BSA) (Sigma, St Louis, Missouri Cat. No. A6003-25G) was diluted to 1 mg/ml. Insulin-TransferrinSelenium (Gibco-Life Technologies Inc., Grand Island, New York, Cat. No. 51500-056) was diluted to 2.5 mg/ml. Antioxidant Supplement 1000Â (Sigma, St Louis, Missouri, Cat. No. A1345-5ML) was diluted to 0.001 ml/ml and Pen-Strep (5000 units Penicillin; 5000 mg/ml streptomycin) (Gibco-Life Technologies Inc., Grand Island, New York, Cat. No. 15070-063) was diluted to 0.01 ml/ml. Culture preparation, maintenance, and dosing. Two rats were used per collection. After euthanasia by CO2 asphyxiation, the animal was placed in dorsal recumbency and the abdomen soaked with 70% ethanol and opened. The mesentery was manually stripped from the intestine and placed intact into a 50 ml conical centrifuge tube containing 25 ml of mesentery digestion solution. The tube was placed on ice until the mesentery was collected from the sceond animal and placed in solution. The tubes were then placed horizontally in a 37 C water bath and shaken at 90 cpm for 2 h. After 2 h, the tubes were placed upright on a benchtop at room temperature for 1 minute to allow tissue chunks to settle, and the supernatant poured into a new tube and filled to 50 ml with Ca-Mg-free HBSS (with 0.1 mg/ml BSA). The tubes were inverted twice to mix, and then centrifuged 250 Â g Â 10 min. The supernatant was discarded, the tube re-filled with Ca-Mg-free HBSS þ BSA, mixed gently to resuspend the cell pellet, and centrifuged again. The second supernatant was discarded and the pellet resuspended in 5 ml of a red blood cell lysis solution. The suspension was allowed to stand at room temperature for 5 min, then filled to 50 ml with HBSS-BSA as above, inverted twice to mix, and spun as above.
The supernatant was aspirated to approximately 2.5 ml and the pellet was resuspended and counted in a CEDEX cell counter (CEDEX HiRes V2.2.1: Roche Diagnostics, Indianapolis, Indiana). The concentrated cells were diluted to 200 000 cells/ml, plated 1 ml per well in a 24-well poly-D-lysine-coated plate and allowed to attach for 48 h before aspirating the medium and treating with test articles. Test articles were dissolved in DMSO, and diluted into cell culture medium to a maximal DMSO concentration of 0.05%. Control wells contained culture medium alone þ DMSO (0.05%). Because our in vivo observations suggested that the initial inflammation began quickly after in vivo dosing, these in vitro exposures were terminated after 6 h, when the cells were rinsed and lysed with 350 ml Qiagen Buffer RLT (Qiagen, Valencia, California Cat. No. 79216) lysis buffer/well and refrigerated until analysis.
Cell characterization
Mesentery cultures were received in tissue culture chambers, scraped with a tissue culture scraper, and fixed in 10% neutral buffered formalin for 1 h. The cells were then washed with PBS, spun down @ 1000g for 10 min, allowed to permeablize at room temperature in a cell block and then paraffin embedded and sectioned @ 5 mm on to glass slides.
Sections were stained for microscopic evaluation and morphological identification with the following stains and antibodies: H&E; Smooth muscle actin "SMA" (Dako, Santa Clara, California, USA, Cat. No. M0851); Vascular endothelial growth factor receptor 2 "VEGF Receptor 2 (55B11)" (Cell Signaling Tech., Danvers, Massachusetts, Cat. No. 2479); Adipophilin (PROGEN, Biotechnik GmbH, Germany); AND Platelet endothelial cell adhesion molecule "CD31" (Abcam, Cambridge, Massachusetts, Cat. No. ab76533).
All samples were deparaffinized through xylene to serial grades of Ethanol 100%, 95%, 70%, to water. Antigen retrieval was performed on all IHC stains and sections were stained on a Biocare automated IHC platform. Antibody detection systems used were as appropriate for the primary antibody and used according to manufacture specifications.
RNA extraction, gene selection, and TLDA analysis Control and treated rat mesentery mixed cell culture samples were collected by washing 3 times with calcium-free PBS followed by immediate lysis and freezing until further use in Qiagen Buffer RLT. Thawed samples were homogenized using the Qiagen Tissue Lyser II at frequency 30 Hz, for 2 min in Qiagen Buffer RLT and stored at 4 C or colder until further use.
The samples were processed through a QiaShredder and total RNA was extracted using the Qiagen RNeasy Mini kit performed on the Qiagen QIAcube instrument following the manufacturer's recommended protocol. Upon completion, the samples were analyzed for concentration via the Nanodrop instrument (Nanodrop products, Wilmington, Delaware, USA) and processed to cDNA. All RNA was converted to sample-specific cDNA libraries using the Applied Biosystem' Supplementary Table  1) . Each TaqMan Gene Expression Assay consisted of a forward and reverse primer at a final concentration of 900 nM and a TaqMan MGB probe (6-FAM dye-labeled), 250 nM final concentration predried down on the custom array. The assays are gene specific and have been designed to span an exon-exon junction. More information about each assay is available through its assay ID number at www.allgenes.com. Specifically, 25 ml of cDNA from each sample (20 ng total input RNA/ml) were combined with an equal volume of TaqMan Universal PCR Master Mix (AB) and molecular biology-grade water, mixed by inversion, and spun briefly in an Eppendorf 5415C microcentrifuge (Brinkmann Instruments, Westbury, New York, USA). After the cards reached room temperature, 100 ml of each sample were loaded into each of 8 ports on the TaqMan Low-Density Array. The cards were placed in Sorvall/Heraeus Custom Buckets (AB) and centrifuged in a Sorvall Legend centrifuge (Kendro Scientific, Asheville, North Carolina, USA) for 1 min at 331 Â g followed closely by another 1 min spin. Cards with excess sample in the fill reservoir were spun for an additional 1 min. Immediately following centrifugation, the cards were sealed with a TaqMan Low-Density Array Sealer (AB) and the loading ports were excised. The final volume in each well after centrifugation was <1.5 ml; thus, the final concentration was approximately 15 ng per reaction. Real time PCR amplifications were run on an Applied Biosystems QuantStudio 12K Flex instrument with a TaqMan Low-Density Array Upgrade and an Automation Accessory. Thermal cycling conditions were as follows: 2 min at 50 C [to activate uracil-DNA glycosylase], 10 min at 95 C (activation), 40 cycles of denaturation at 95 C for 15 s, and annealing and extension at 60 C for 1 min. Eight samples were processed on each card. Three biological replicates were run for each sample. Real-time RT-PCR data were examined for outliers and overall quality and then quantified using the Applied Biosystems ExpressionSuite software package. Results from each array were quantified concurrently, using an automatic baseline and threshold to determine the cycle thresholds. Visual inspection of automatic settings was conducted for each dataset and adjusted as necessary. Assays that did not yield a cycle threshold for < 40 cycles were treated as negative results. For our analysis, we used the delta delta C t relative quantification method built into the ExpressionSuite Software (Livak and Schmittgen, 2001; Schmittgen and Livak, 2008) . Confidence intervals of 95% were based on the technical and biological replicates and were used to plot the x and y error bars in Microsoft Excel. All data were reported as fold change over concurrent control for each experiment. At least 2 replicate experiments were performed for each treatment with concurrent controls.
Data analyses
Expression data from all 96 genes on the TaqMan Gene Expression Assays were analyzed using 4 machine learning approaches. Expression data from DIVI-negative and DIVIpositive compounds at concentrations below that known to induce DIVI were regarded as negatives for the purpose of model training. Missing values were replaced with zero. All compounds and concentrations were run in triplicate. The Rlibrary "caret" was used to evaluate the predictive value of the data using C5.0 Boost Tree, Generalized Linear, Random-Forest (RF) and Support Vector Machine learning approaches (Kuhn, 2008) . Using 10-fold cross validation with 25% of the data withheld for testing, the RF model was selected as scoring amongst the best methods. Variable importance from the RF model was used to identify the 9 genes which contributed the most to the predictivity. Expression data from these genes plus 7 others was then used to cross-validate the methodology using a leave-oneout approach. Each compound was tested in turn by building a DIVI prediction RF model on the expression data from the other 8 compounds. For each held out compound, the probability of DIVI was calculated at each drug concentration. The concentration at which the probability exceeded 50% was considered to be the DIVI point.
RESULTS
To test our hypothesis that a primary culture of mixed rat mesentery cells could be used to identify a gene signature of DIVI consistent with a direct inflammatory response, we chose as positive examples 5 PDE4i for which the lowest plasma concentration at which a DIVI phenotype had been observed in rats was known (Table 1) . As negative controls, we selected 4 diverse compounds that did not induced DIVI at any concentration tested. Mesentery cells were treated with each compound separately over a 5-fold dilution series of 7 concentrations. The maximum concentration was set to approximately 300Â the Ceff. The maximal concentration of 100 mg/ml was known not to induce cell death for any compounds (data not shown). Figure 1 shows a representative field of cells after plating. Extensive efforts were made to characterize the different celltypes in the mixed-mesentery tissue samples. Our efforts to apply different staining techniques were confounded by an inability of the cells to remain bound to the plate through the successive washings, and staining loose cells was not possible. Nevertheless, the different morphologies can be appreciated from the photomicrograph. Although our characterization work did not yield the quantitation we desired, the heterogeneity in the mixed cell preparation is readily apparent. Representative micrographs of some of the immunostained tissue samples are in a Supplementary Material (Supplementary PowerPoint).
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Generation of Data and Modeling
Data from DIVI positive and negative compounds were initially analyzed using a TaqMan Gene Expression array panel of 96 genes involved in inflammatory disease. Data from all 9 compounds were used to evaluate a number of machine learning models to determine which could best predict the lowest drug free C max at which DIVI was observed in rats. The "caret" Rlibrary package was used to evaluate C5.0 Boost Tree, RandomForest, support-vector machine and generalized linear model as the best means to predict DIVI (Kuhn, 2008) . Receiver operating characteristic (ROC) curve analysis indicated that 3 out of 4 models were very successful, with ROC values averaging around 0.93. The generalized linear model was less predictive with a ROC value of 0.68. (Figure 2 ) Based on these results, the RF model was chosen because the approach allows the determination of the importance of each variable to the resulting model. We could then use this feature to identify a limited set of highly predictive genes which could be used to create a custom TaqMan array. Examining the RF model in more detail, we found that, by a number of measures, the model yielded a very high level of predictivity (Table 2 ). Since one aim of this work was to develop a DIVI-prediction array, we needed to select 16 genes for inclusion on a custom array. One-hundred-fold crossvalidation of the model revealed that 9 genes (Crem, Il6, Il11, Vegfa, Cx3cl1, Timp1, Serpine1, Cxcl1, and Il1b) contributed most to the predictive power. Briefly, the TaqMan expression data was randomly divided into a training set (75% of the data) and a test set. A RF model was built from the training data and used to evaluate the test data. The VarImp (variable importance) function within RF was used to determine which genes expression values contributed the most to the model. This splitting of the data and evaluating on a test set of expression data was repeated 100 times. The relative predictive contribution of each gene was averaged over the 100 repeats and the 9 genes which contributed the most were selected. These genes, together with 3 inflammatory genes identified from previous DIVI studies (Il33, S100a8, and Pla2g5) and the housekeeping genes (18S, Actb, and Rpl13a) were selected for detailed reanalyses (see Supplementary Table 1 for TaqMan probes). We also added the inflammatory gene Nfkb1 to the custom array however it was not on the original TaqMan Array Rat Inflammation Panel array used for this work so data for its expression was unavailable for re-analysis.
Leave One Out DIVI Predictions
In the analyses of the data from the Rat Inflammation Panel array, expression data from 25% of the samples were randomly removed for testing while the remaining 75% were used to build the RF model. However, this approach leaves open the possibility that some expression data from every compound would be found in the training data resulting in over-confidence in the ability of the model to predict DIVI in novel compounds. To address this concern, with the 16-gene custom TaqMan array, we used a modified leave-one-out cross-validation approach to build and test the model. In this case, all expression data from one compound were omitted and a RF model built using data from the other 8 compounds. The resulting RF model was then used to predict the probability of a DIVI response at each of the concentrations for the compound being tested. Figure 3 shows the resulting plots of DIVI probability versus concentration for the initial 9 compounds.
DISCUSSION
PDE4i show significant promise in a variety of therapeutic areas ranging from schizophrenia to chronic obstructive pulmonary disease (Brown, 2007; Kanes et al., 2007) . However, development of these compounds has been challenging due to findings of vascular lesions in rats, dogs and monkeys (Enerson et al., 2006; Larson et al., 1996; Losco et al., 2004) . These DIVI lesions often occur in the absence of any clinical observations or systemic hemodynamic effects. Although a number of mechanisms have been postulated for these lesions, the current thinking is that these drugs induce a localized injury, which induces an inflammatory response that ultimately drives the vascular injury. Given the localized nature of this process it does not result in systemic hemodynamic alterations. Thus, no sensitive and specific biomarkers of these early changes exist either in humans or preclinical animal models. Therefore, the development of DIVI prone compounds for many indications relies heavily on having a sufficient safety margin prior to testing in humans. This has placed a high emphasis on identifying a good in vitro method to screen compounds in search of molecules with low DIVI risk.
In this report, we examined the utility of isolated mixed mesentery tissue to build a gene expression model that could detect potential DIVI compounds early. Although inflammation appears to play an early key role in the development of DIVI with PDE4i's, the cell types initiating the inflammatory response are not known. We therefore chose to use a model which contained all the cells from the mesentery rather than 1 or 2 cell types. Using these mixed cells, we found that a number of machine learning techniques could be applied to the expression of 96 inflammation-linked genes to yield highly predictive models of DIVI over a range of concentrations (Figure 2 ). Closer examination of one of these techniques, RF modeling, revealed that a model could be developed which was capable of accurately predicting DIVI response from >90% of the samples without losing specificity (Table 2A) . Based on this initial analysis, 9 genes (Crem, Il6, Il11, Vegfa, Cx3cl1, Timp1, Serpine1, Cxcl1, and Il1b) were identified as being the most important to the prediction model. Most of these genes had been identified in previous studies as potential DIVI biomarkers (Dagues et al., 2007; Dalmas et al., 2008; Mikaelian et al., 2014; Weaver et al., 2010) . However, we were unable to find mention of either IL-11 or Cx3cl1 (fractalkine) as potential DIVI biomarkers. Nonetheless both genes have been reported to play a role in vascular injury (Demyanets et al., 2012; Kasama et al., 2010; Mahboubi et al., 2000) . Limiting the RF model to 16 genes did not significantly impact the predictivity of the resulting model (Table 2B) .
One potential concern in our initial analysis is that for any one compound, our data has expression data from multiple concentrations and replicates. This could potentially lead to over-confidence in the model since it likely contained as least (A) RF modeling using all genes and all compound data. Compound data were randomly divided into training data (75%) and the remaining 25% reserved for testing. Modeling was repeated 100Â. (B) RF modeling using 15 genes selected for the custom chip and all compound data. Compound data was randomly divided into training data (75%) and the remaining 25% reserved for testing. Modeling was repeated 100Â. (C) RF modeling using 15 genes selected for the custom chip and one compound data set held out for testing. All data for an individual compound was held out for testing while the remaining data was used for training. PPV, positive predictive value;
NPV, negative predictive value.
one or more expression sets from every compound. Since we wished to determine if the model would be useful for the prediction of DIVI in novel compounds, we used a modified leaveone-out cross-validation approach to test the model. To perform the test, we removed all the expression data for one compound, built the RF model with the data from the other 8 compounds and then tested the ability of the model to predict the DIVI response in the removed data. By all measures tested, the overall reliability of the approach remained very high (Table  2C) . We next examined the individual predictions from each sample and plotted the DIVI prediction against drug concentrations ( Figure 3) . All of the negative compounds were predicted to be negative except for 2 samples from one replicate. The predictions for the positive compounds generally reflected the concentrations at which the compounds induced DIVI in rats (Table 3 ). Based on the success of our model to predict DIVI with PDE4i compounds, we attempted to use the 16-gene custom TaqMan array and the random forest model to predict DIVI with nonPDE4i chemicals. In this experiment, we examined 9 new compounds known to induce DIVI in rats. The mechanisms of actions included Rho kinase inhibitors, a PDE2 inhibitor, a PDE10 inhibitor, dopamine receptor agonists, an ACC inhibitor, an anti-malarial, a LRRK2 inhibitor and a PDE4 inhibitor (not tested in the above experiment). Of all positive compounds, only the novel PDE4 inhibitor was predicted to be positive for DIVI (data not shown). While disappointing, the results were not unexpected as the DIVI positive compounds used to build the model were exclusively from PDE4i's. The 96 inflammatory genes originally selected were chosen based on the hypothesized inflammatory mechanism behind PDE4i-induced DIVI. Additionally, the 6-h time point was selected based on previous work done with PDE4i-induced DIVI. These results do not preclude the possibility that building a mesentery tissue model from DIVI-positive compounds with a diverse MOA and using an unbiased expression approach such as RNA-SEQ Next-Generation Sequencing with samples taken over a range of time points could result in a better predictive model.
In conclusion, the use of mixed mesentery tissues can be used to build a highly predictive model of PDE4i-induced vascular injury in rats. Since all tissue types were included in the assays, any compound-induced intercellular signaling effect leading to inflammation should also be recapitulated in our model system. The previously reported in vivo inflammatory effects of PDE4i's were easily detected in this in vitro assay. In this experiment, we focused on an inflammatory mechanism of DIVI; however other compounds are believed to induce DIVI through different mechanisms. Our results demonstrate that mixed mesenteric tissues reflect the in vivo biology of whole animals and the results suggest that this system could be employed to model other biologic mechanisms.
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